127 related articles for article (PubMed ID: 8528270)
1. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.
Crespi CL; Steimel DT; Penman BW; Korzekwa KR; Fernandez-Salguero P; Buters JT; Gelboin HV; Gonzalez FJ; Idle JR; Daly AK
Pharmacogenetics; 1995 Aug; 5(4):234-43. PubMed ID: 8528270
[TBL] [Abstract][Full Text] [Related]
2. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
[TBL] [Abstract][Full Text] [Related]
3. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.
Penman BW; Reece J; Smith T; Yang CS; Gelboin HV; Gonzalez FJ; Crespi CL
Pharmacogenetics; 1993 Feb; 3(1):28-39. PubMed ID: 8485585
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
[TBL] [Abstract][Full Text] [Related]
6. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
7. High yield expression of functionally active human liver CYP2D6 in yeast cells.
Krynetski EY; Drutsa VL; Kovaleva IE; Luzikov VN
Pharmacogenetics; 1995 Apr; 5(2):103-9. PubMed ID: 7663527
[TBL] [Abstract][Full Text] [Related]
8. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.
Narimatsu S; Kato R; Horie T; Ono S; Tsutsui M; Yabusaki Y; Ohmori S; Kitada M; Ichioka T; Shimada N; Kato R; Ishikawa T
Chirality; 1999; 11(1):1-9. PubMed ID: 9914647
[TBL] [Abstract][Full Text] [Related]
9. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
[TBL] [Abstract][Full Text] [Related]
12. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
14. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
15. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver.
Hichiya H; Takemi C; Tsuzuki D; Yamamoto S; Asaoka K; Suzuki S; Satoh T; Shinoda S; Kataoka H; Narimatsu S
Biochem Pharmacol; 2002 Oct; 64(7):1101-10. PubMed ID: 12234613
[TBL] [Abstract][Full Text] [Related]
16. Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan.
Rodrigues AD; Kukulka MJ; Surber BW; Thomas SB; Uchic JT; Rotert GA; Michel G; Thome-Kromer B; Machinist JM
Anal Biochem; 1994 Jun; 219(2):309-20. PubMed ID: 8080088
[TBL] [Abstract][Full Text] [Related]
17. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver.
Mankowski DC; Laddison KJ; Christopherson PA; Ekins S; Tweedie DJ; Lawton MP
Arch Biochem Biophys; 1999 Dec; 372(1):189-96. PubMed ID: 10562433
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
20. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
